Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.

The Danish drugmaker is lowering the price of the drugs for existing cash-paying patients to $349 per month from $499 per month. But Novo Nordisk said the cash-pay cost of the highest dose of Ozempic will remain $499 per month.

Also on Monday, Novo Nordisk launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. After that period, people move to the new standard monthly direct-to-consumer price. Th

See Full Page